HIPEC 对接受细胞减灭术治疗的复发性卵巢癌患者有效

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-11-26 DOI:10.1038/s41571-024-00973-0

Peter Sidaway

{"title":"HIPEC 对接受细胞减灭术治疗的复发性卵巢癌患者有效","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00973-0","DOIUrl":null,"url":null,"abstract":"Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting.In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with disease recurrence ≥6 months after completion of chemotherapy received 6 cycles of preoperative platinum-doublet chemotherapy (with or without bevacizumab). The 415 patients deemed eligible for cytoreductive surgery were then randomly allocated 1:1 to receive surgery with versus without cisplatin HIPEC. OS was the primary end point.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"188 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer\",\"authors\":\"Peter Sidaway\",\"doi\":\"10.1038/s41571-024-00973-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting.In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with disease recurrence ≥6 months after completion of chemotherapy received 6 cycles of preoperative platinum-doublet chemotherapy (with or without bevacizumab). The 415 patients deemed eligible for cytoreductive surgery were then randomly allocated 1:1 to receive surgery with versus without cisplatin HIPEC. OS was the primary end point.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"188 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-024-00973-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00973-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

晚期卵巢癌晚期复发的妇女通常会接受术前化疗，然后进行细胞减灭术。在这项试验中，共有517名患有复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌且在化疗结束后复发≥6个月的妇女接受了6个周期的术前铂类双联化疗（使用或不使用贝伐单抗）。然后，415名被认为符合细胞切除手术条件的患者按1:1的比例随机分配接受顺铂HIPEC手术和不接受顺铂HIPEC手术。OS是主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer

Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting.

In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with disease recurrence ≥6 months after completion of chemotherapy received 6 cycles of preoperative platinum-doublet chemotherapy (with or without bevacizumab). The 415 patients deemed eligible for cytoreductive surgery were then randomly allocated 1:1 to receive surgery with versus without cisplatin HIPEC. OS was the primary end point.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.